FDA 米诺环素口服与注射产品：新增嗜麦芽窄食单胞菌药敏折点
Minocycline Oral, Injection products
FDA 公布米诺环素口服与注射产品的药敏试验解释标准例外或补充内容，新增嗜麦芽窄食单胞菌折点：MIC 敏感≤2、耐药≥4 mcg/mL，纸片扩散法敏感21-25 mm、耐药≤20 mm，基于每12小时200 mg静脉或口服给药。对四环素敏感的炭疽芽孢杆菌、土拉弗朗西斯菌、霍乱弧菌和鼠疫耶尔森菌亦视为对米诺环素敏感；其他非肠杆菌目及肠球菌属暂未认可药敏解释标准。
Exceptions or additions to the recognized standards
Minimum Inhibitory Concentration (mcg/mL) | Disk Diffusion | |||||
|---|---|---|---|---|---|---|
| Pathogen | S | I | R | S | I | R |
| Stenotrophomonas maltophilia | - | 2 | ≥ 4 | - | 21-25 | ≤ 20 |
Abbreviations: S = susceptible; I = intermediate; R = resistant.
Breakpoints are based on a dosage of 200 mg intravenously/orally every 12 hours.
The following organisms that are susceptible to tetracycline are also considered susceptible to minocycline: Bacillus anthracis, Franciscella tularensis, Vibrio cholera, Yersinia pestis.
For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:
Other Non-Enterobacterales
Enterococcus spp.
来源：FDA 官方药品与生物制品信息 · fda.gov